Washington, D.C. 20549


FORM 12b-25








040221 202


(Check one):   o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D
    o Form N-SAR o Form N-CSR      
    For Period Ended: September 30, 2018
    o Transition Report on Form 10-K    
    o Transition Report on Form 20-F    
    o Transition Report on Form 11-K    
    o Transition Report on Form 10-Q    
    o Transition Report on Form N-SAR    
    For the Transition Period Ended:  


Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:





Argos Therapeutics, Inc.
Full Name of Registrant
Former Name if Applicable
4233 Technology Drive
Address of Principal Executive Office (Street and Number)
Durham, North Carolina 27704
City, State and Zip Code


PART II - RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


  (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.








State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


Argos Therapeutics Inc. (the "Company") is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended September 30, 2018 (the "Quarterly Report") by November 14, 2018 filing date due date to a delay experienced by the Company in completing its financial statements and other disclosures in the Quarterly Report caused by the Company's limited number of personnel and the Company’s pursuit of a strategic alternative, including an asset sale, dissolution, liquidation or protection under bankruptcy laws. As a result, the Company is still in the process of compiling required information to complete the Quarterly Report. The Company anticipates that it will file the Quarterly Report within the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934.




(1) Name and telephone number of person to contact in regard to this notification
  Richard Katz   (919)   287-6315
  (Name)   (Area Code)   (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
          x Yes    o No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
          x Yes    o No





If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


In April 2018, the Company terminated its development program for rocapuldencel-T, which it had been developing for the treatment of metastatic renal cell carcinoma and other cancers. As a result, the Company’s research and development expenses for the three and nine months ended September 30, 2018 are expected to be less than for the same periods in 2017. Due to the exploration of a strategic alternative, including an asset sale, dissolution, liquidation or protection under bankruptcy laws, the Company is not able to provide an estimate of results of operations at this time.



Forward-looking statements


Except for statements of historical fact, the matters discussed in this Form 12b-25 are “forward-looking statements” within the meaning of the applicable securities laws and regulations. The words “estimates”, “expects” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements, including statements regarding the Company’s estimates of its operating results for the three and nine months ended September 30, 2018, involve risks and uncertainties that may cause actual results to differ materially from those stated here. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risk that additional information may arise from the completion of the review of the Company’s results of operations, as well as other risks described more fully in the Company’s filings with the SEC. Forward-looking statements reflect management’s analysis as of the date hereof. The Company does not undertake to revise these statements to reflect subsequent developments.







Argos Therapeutics, Inc.


(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 14, 2018   By: /s/ Richard Katz
      Name: Richard Katz
      Title: Vice President and Chief Financial Officer


INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.


Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).